Effect of Zhengyuan capsules on post-chemotherapy appetite loss and cancer-related fatigue in patients with advanced lung cancer
- 1Department of Oncology,The First Affiliated Hospital with Nanjing Medical University,Nanjing,Jiangsu 210029,China
Abstract
Objective To evaluate the clinical efficacy of Zhengyuan capsules in improving appetite loss and cancer-related fatigue in patients with advanced lung cancer receiving standard chemotherapy. Methods Clinical data were collected from 110 advanced lung cancer patients who received chemotherapy in the Oncology Department of the First Affiliated Hospital with Nanjing Medical University from March 2025 to September 2025. Patients were divided into the control group(55 cases receiving standard chemotherapy)and the experimental group(55 cases receiving Zhengyuan capsules orally for 21 days in addition to the same standard chemotherapy of control group). Visual Analogue Scale for appetite/food intake and Brief Fatigue Inventory(BFI)were used to assess changes in appetite loss and fatigue severity on day 1(d1)and day 7(d7)of chemotherapy,while chronic inflammatory index fibrinogen-to-albumin ratio(FAR)was analyzed. Results Baseline characteristics showed no significant difference between the two groups(P>0.05). On d1 of chemotherapy,there was no statistically significant difference in appetite,food intake and fatigue score between the two groups(P>0.05). On d7 of chemotherapy,the experimental group demonstrated significantly higher appetite score［8(8,8)vs 2(2,2),Z=9.902,P<0.01］and food intake score［6(6,6)vs 3(3,3),Z=9.706,P<0.01］,and significantly lower fatigue score［1(1,1)vs 4(4,4),Z=9.293,P<0.01］compared with the control group. The FAR in the experimental group was significantly lower than that in the control group［0.08(0.07,0.09)vs 0.10(0.08,0.10),P=0.031］. Using FAR=0.09 as the cutoff value,110 patients were divided into a high-FAR group(FAR≥0.09,n=57)and a low-FAR group(FAR＜0.09,n=53). The high-FAR group had a higher d7 BFI score compared to the low-FAR group［4(1,4)vs 1(1,4),P=0.029］. Conclusion Zhengyuan capsules can significantly improve appetite loss and cancer-related fatigue in advanced lung cancer patients undergoing standard chemotherapy,and its mechanism may be associated with reducing chronic inflammation.
Related
- Efficacy and safety of narlumosbart in combination with stereotactic body radiation therapy followed by first-line chemotherapy combined with immunotherapy in advanced driver gene-negative non-small cell lung cancer patients with bone metastases: a phase II, single-arm, single-centre clinical trial protocol
- Clinical outcomes of first-line nivolumab plus chemotherapy in patients aged ≥ 75 years with unresectable advanced or recurrent gastric cancer: a retrospective study.
- Effect of Acupuncture for Loss of Appetite in Advanced Lung Cancer Undergoing Immunotherapy: Protocol of a Randomized Controlled Trial
- Study protocol for a randomized, double-blind, placebo-controlled clinical trial to assess chemoprotective efficacy of Aqueous standardized extract of Tinospora cordifolia (AsSET) in patients receiving Docetaxel based chemotherapy for advanced / metastatic solid tumors
- Neoadjuvant chemotherapy in locally advanced colon cancer: lessons from the NeoCol trial and the limits of anatomical risk stratification.
BibTeX
@article{yi2026effect,
title = {{Effect of Zhengyuan capsules on post-chemotherapy appetite loss and cancer-related fatigue in patients with advanced lung cancer}},
author = {JIAO Yi and ZHANG Zheyuan and YUAN Luhongying and CHEN Yiting and MENG Lijuan},
journal = {Zhongguo linchuang yanjiu},
year = {2026},
month = oct,
doi = {10.13429/j.cnki.cjcr.2026.10.004},
url = {https://doi.org/10.13429/j.cnki.cjcr.2026.10.004},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Effect of Zhengyuan capsules on post-chemotherapy appetite loss and cancer-related fatigue in patients with advanced lung cancer
AU - JIAO Yi
AU - ZHANG Zheyuan
AU - YUAN Luhongying
AU - CHEN Yiting
AU - MENG Lijuan
PY - 2026
DA - 2026/10/26
JO - Zhongguo linchuang yanjiu
DO - 10.13429/j.cnki.cjcr.2026.10.004
UR - https://doi.org/10.13429/j.cnki.cjcr.2026.10.004
AB - Objective To evaluate the clinical efficacy of Zhengyuan capsules in improving appetite loss and cancer-related fatigue in patients with advanced lung cancer receiving standard chemotherapy. Methods Clinical data were collected from 110 advanced lung cancer patients who received chemotherapy in the Oncology Department of the First Affiliated Hospital with Nanjing Medical University from March 2025 to September 2025. Patients were divided into the control group(55 cases receiving standard chemotherapy)and the experimental group(55 cases receiving Zhengyuan capsules orally for 21 days in addition to the same standard chemotherapy of control group). Visual Analogue Scale for appetite/food intake and Brief Fatigue Inventory(BFI)were used to assess changes in appetite loss and fatigue severity on day 1(d1)and day 7(d7)of chemotherapy,while chronic inflammatory index fibrinogen-to-albumin ratio(FAR)was analyzed. Results Baseline characteristics showed no significant difference between the two groups(P>0.05). On d1 of chemotherapy,there was no statistically significant difference in appetite,food intake and fatigue score between the two groups(P>0.05). On d7 of chemotherapy,the experimental group demonstrated significantly higher appetite score［8(8,8)vs 2(2,2),Z=9.902,P<0.01］and food intake score［6(6,6)vs 3(3,3),Z=9.706,P<0.01］,and significantly lower fatigue score［1(1,1)vs 4(4,4),Z=9.293,P<0.01］compared with the control group. The FAR in the experimental group was significantly lower than that in the control group［0.08(0.07,0.09)vs 0.10(0.08,0.10),P=0.031］. Using FAR=0.09 as the cutoff value,110 patients were divided into a high-FAR group(FAR≥0.09,n=57)and a low-FAR group(FAR＜0.09,n=53). The high-FAR group had a higher d7 BFI score compared to the low-FAR group［4(1,4)vs 1(1,4),P=0.029］. Conclusion Zhengyuan capsules can significantly improve appetite loss and cancer-related fatigue in advanced lung cancer patients undergoing standard chemotherapy,and its mechanism may be associated with reducing chronic inflammation.
SN - 1674-8182
ER -